摘要：肝癌是世界上第三大最常見的致死性癌癥。肝癌的治療手段需要多學科技術的參與，具體實施取決于腫瘤病程的分期、病人的身體機能和肝功能。在過去的數(shù)年內(nèi)，肝癌的手術治療和局部治療取得重大的進展，短期存活率提高，但復發(fā)和轉移依舊是治療的難題。對于中晚期肝癌患者而言，介入治療是近年來應用較為廣泛的一種微創(chuàng)治療手段，通過注射特殊的藥劑進入腫瘤的血管，，直接干預腫瘤的生長，破壞組織，促進腫瘤細胞的凋亡，具有良好的治愈效果。本文對介入治療進行深入分析，收集其參與體內(nèi)免疫系統(tǒng)的調(diào)節(jié)，促進或抑制癌癥相關的信號通路的作用，進一步闡述治療手段的作用機制，并為治療手段的發(fā)展和靶向提供新的啟發(fā)和理論支持。
關鍵詞：肝癌、介入治療、信號通路、免疫系統(tǒng)

Abstract: 

Hepatocellular carcinoma is the third most common death-related type of cancer. The treatments for hepatocellular carcinoma patients require multidisciplinary technical participation with the specific implemention depending on the cancer staging, physical status of patients and liver function.In the past few years, a great progression has been made in operation therapy and local treatment of Hepatocellular carcinoma by increasing the short-term survival rate. But it’s still a huge problem the recurrence and metastasisi of tumor issues. For patients with adcanced cancer, Interventional therapy is a widely used minimally invasive treatment in recent years. By injecting some special agent into the tumor vessels or other non-cascular cavities, the tumor issue would obtain an inhibition of the growth and induction of the apoptosis of cancer cells. This article has taken a depth analysis on interventional therapy mechanism, including the regulation of the immune system and cancer-related signal pathway, and provide new inspiration and theoretical supporting for therapy of hepatocellular carcinoma.
Key words: Hepatocellular carcinoma (HCC), interventional therapy, treatment mechanism 

（一） 肝癌的分期
表1. BCLC肝癌分期參照表
圖1. 肝癌分期和治療方案對照圖
 
（二） 肝癌的非血管性介入治療
（1）射頻消融治療
（2）化學消融治療
（三） 血管性介入治療
（1） 肝動脈化療栓塞
（2） 藥物洗脫珠化療栓塞
（四） 聯(lián)合介入治療
（1） TACE+射頻消融
（2） TACE+化學消融
（3） TACE+基因治療

文獻

1. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94(6):1760-9.
2. Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Seminars in cancer biology. 2014;26:78-88.
3. Takayama T, Makuuchi M, Kojiro M, Lauwers GY, Adams RB, Wilson SR, et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Annals of surgical oncology. 2008;15(4):972-8.
4. Karaman B, Battal B, Sari S, Verim S. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World journal of gastroenterology : WJG. 2014;20(47):18059-60.
5. Duseja A. Staging of hepatocellular carcinoma. Journal of clinical and experimental hepatology. 2014;4(Suppl 3):S74-9.
6. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2004;10(2 Suppl 1):S115-20.
7. Yang T, Lin C, Zhai J, Shi S, Zhu M, Zhu N, et al. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. Journal of cancer research and clinical oncology. 2012;138(7):1121-9.
8. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of hepatology. 2006;44(4):723-31.
9. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54(3):411-8.
10. Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer imaging : the official publication of the International Cancer Imaging Society. 2012;12:79-88.
11. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities--part II. Journal of vascular and interventional radiology : JVIR. 2001;12(10):1135-48.
12. Facciorusso A, Del Prete V, Antonino M, Crucinio N, Neve V, Di Leo A, et al. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2014;46(11):1014-9.
13. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Annals of surgery. 2009;249(1):20-5.
14. Peng ZW, Zhang YJ, Chen MS, Liang HH, Li JQ, Zhang YQ, et al. Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. Surgical oncology. 2008;17(1):23-31.
15. Gervais DA, Arellano RS. Percutaneous tumor ablation for hepatocellular carcinoma. AJR American journal of roentgenology. 2011;197(4):789-94.
16. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology (Baltimore, Md). 2001;34(4 Pt 1):707-13.
17. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54(8):1151-6.
18. Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. International journal of radiation oncology, biology, physics. 2003;57(1):113-9.
19. Tavernier J, Fagnoni P, Chabrot P, Guiu B, Vadot L, Aho S, et al. Comparison of two transarterial chemoembolization strategies for hepatocellular carcinoma. Anticancer research. 2014;34(12):7247-53.
20. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR American journal of roentgenology. 2010;194(3):830-7.
21. Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. Journal of surgical oncology. 2000;73(2):109-14.
22. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. European journal of radiology. 2009;72(3):505-16.
23. Daniels JR. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR American journal of roentgenology. 2011;196(2):W220.
24. Li G, Dong S, Qu J, Sun Z, Huang Z, Ye L, et al. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver. 2010;30(4):585-92.
25. Kensler TW, Egner PA, Wang JB, Zhu YR, Zhang BC, Lu PX, et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology. 2004;127(5 Suppl 1):S310-8.
26. Liu YS, Ou MC, Tsai YS, Lin XZ, Wang CK, Tsai HM, et al. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Korean journal of radiology : official journal of the Korean Radiological Society. 2015;16(1):125-32.
27. Harada T, Matsuo K, Inoue T, Tamesue S, Inoue T, Nakamura H. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Annals of surgery. 1996;224(1):4-9.
28. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. Journal of hepatology. 2012;56(6):1330-5.
29. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. Journal of hepatology. 2007;46(3):474-81.
30. Ferrer Puchol MD, la Parra C, Esteban E, Vano M, Forment M, Vera A, et al. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Radiologia. 2011;53(3):246-53.
31. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of hepatology. 2001;35(3):421-30.
32. Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Advances in therapy. 2008;25(8):787-94.
33. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). European radiology. 2006;16(3):661-9.
34. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(4):426-32.
35. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World journal of gastroenterology : WJG. 2005;11(39):6104-9.
36. Wang N, Guan Q, Wang K, Zhu B, Yuan W, Zhao P, et al. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Medical oncology (Northwood, London, England). 2011;28(4):1038-43.
37. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 2007;72 Suppl 1:30-44.
38. Lencioni R, Cioni D, Donati F, Bartolozzi C. Combination of interventional therapies in hepatocellular carcinoma. Hepato-gastroenterology. 2001;48(37):8-14.
39. Xiao EH, Li JQ, Huang JF. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization. World journal of gastroenterology : WJG. 2004;10(2):190-4.

本文編號：128561